Zentalis Pharmaceuticals (ZNTL) Insider & Congress Trades

Smart money at a glance

Filings to Nov 1, 2026

Net buying: insiders sold $0 and bought $15.2M on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: +$15.2M netNet buying
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 0 cutMore adding

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about ZNTL filings

Are insiders buying or selling Zentalis Pharmaceuticals Llc (ZNTL) stock?

Net buying: insiders sold $0 and bought $15.2M of ZNTL stock on the open market in the 90 days to Nov 1, 2026, according to SEC Form 4 filings. The largest was Walters, Susan Berkley (10% owner), who bought $15.2M. The latest filing was on Aug 19, 2026.

Which members of Congress have traded ZNTL recently?

None. No member of Congress disclosed a ZNTL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ZNTL smart-money data?

This summary uses filings available on Nov 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on ZNTL

Lean long2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
- Walters Group, bought $15.2M, open market, filed Aug 19
Lean long · thin1 buy · $15.2M
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
- BlackRock, added +$15.2M, holdings at Jun 30
Lean long · thin1 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ZNTL filings

Are insiders buying or selling Zentalis Pharmaceuticals Llc (ZNTL) stock?

Which members of Congress have traded ZNTL recently?

None. No member of Congress disclosed a ZNTL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ZNTL smart-money data?

Funds

What funds are doing

1 move · 6 mo

Buys/Adds$15.2M

Buys/Adds (1)

BR
BlackRock
Q2 2026 13F
$15.2M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 5, 2026

Earnings came in 31.1% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 5, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.59-31.11% miss

-$0.45 expected

Revenue (FY)

$0.00

Year ended Dec 31, 2025 · SEC filing

Next report

Estimated report: Nov 9, 2026, in 8 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 5, 2026	-$0.59est. -$0.45	-31.11%miss	Not on file	Not on file
Mar 31, 2026Reported May 12, 2026	-$0.50est. -$0.47	-7.43%miss	Not on file	Not on file
Dec 31, 2025Reported Mar 26, 2026	-$0.49est. -$0.61	+19.67%beat	$0.00 · FYSEC filing	No year-ago quarter
Sep 30, 2025Reported Nov 10, 2025	-$0.37est. -$0.48	+22.92%beat	$0.00SEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 6, 2025	-$0.37est. -$0.52	+28.85%beat	$0.00SEC filing	No year-ago quarter
Mar 31, 2025Reported May 14, 2025	-$0.67est. -$0.61	-9.84%miss	$0.00SEC filing	-100.0%from $40.6M
Dec 31, 2024Reported Mar 26, 2025	-$0.61est. -$0.68	+9.96%beat	$67.4M · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 12, 2024	-$0.56est. -$0.87	+35.63%beat	$0.00SEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.99
52-wk high: $6.95
High: $1.99
52-wk low: $1.21
Low: $1.86
Prev close: $1.99
Mkt cap: $192.3M
ROE: -66.7%
Beta: 1.94
P/S: 4.4x
P/B: 1.3x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $192M

Valuation

P/S4.42
P/B1.30

Quality

Operating margin0.0%
ROE-66.7%
ROA-33.2%

Growth

Beta1.94

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

29oversold

20D volatility

79%annualized

52-week range

$1.96

$1.21$6.95

20D support

$1.86recent floor

20D resistance

$2.84recent ceiling

Returns

5D -11.3%20D -22.2%60D -60.8%

Price vs moving averages

SMA20 -15.7%SMA50 -33.5%SMA200 -43.3%

Volume pace

1.05xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Jun 30, 2026Aug 5, 2026

-$0.59est. -$0.45

-31.11%

Not on file

Mar 31, 2026May 12, 2026

-$0.50est. -$0.47

-7.43%

Not on file

Dec 31, 2025Mar 26, 2026

-$0.49est. -$0.61

+19.67%

$0.00 · FYSEC filing

No year-ago quarter

Sep 30, 2025Nov 10, 2025

-$0.37est. -$0.48

+22.92%

$0.00SEC filing

No year-ago quarter

Jun 30, 2025Aug 6, 2025

-$0.37est. -$0.52

+28.85%

$0.00SEC filing

No year-ago quarter

Mar 31, 2025May 14, 2025

-$0.67est. -$0.61

-9.84%

$0.00SEC filing

-100.0%from $40.6M

Dec 31, 2024Mar 26, 2025

-$0.61est. -$0.68

+9.96%

$67.4M · FYSEC filing

No year-ago quarter

Sep 30, 2024Nov 12, 2024

-$0.56est. -$0.87

+35.63%

$0.00SEC filing

No year-ago quarter

Zentalis Pharmaceuticals Llc

Smart money at a glance

What do analysts expect?

Questions about ZNTL filings

Smart money on ZNTL

Questions about ZNTL filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 31.1% below what analysts expected.

Estimated report: Nov 9, 2026, in 8 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Zentalis Pharmaceuticals Llc

Smart money at a glance

What do analysts expect?

Questions about ZNTL filings

Smart money on ZNTL

Questions about ZNTL filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 31.1% below what analysts expected.

Estimated report: Nov 9, 2026, in 8 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Zentalis Pharmaceuticals Llc

Overview

Questions about ZNTL filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Zentalis Pharmaceuticals Llc

Overview

Questions about ZNTL filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.